A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy

Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamegai, Kohei, Iwamoto, Noriko, Togano, Tomiteru, Maeda, Kenji, Takamatsu, Yuki, Miyazato, Yusuke, Ishikane, Masahiro, Mizokami, Masashi, Sugiyama, Masaya, Iida, Shun, Miyamoto, Sho, Suzuki, Tadaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054701/
https://www.ncbi.nlm.nih.gov/pubmed/35500795
http://dx.doi.org/10.1016/j.ijid.2022.04.058
Descripción
Sumario:Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.

Ejemplares similares